Search in:

OncoTargets and Therapy Volume 10, 2017 - Issue

Submit an article Journal homepage

Open access

Views

CrossRef citations to date

Altmetric

Review

Is this the end of cytotoxic chemotherapy in Merkel cell carcinoma?

Guilherme RabinowitsDepartment of Medical Oncology, Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, MA, USACorrespondence[email protected]

Pages 4803-4807 | Published online: 28 Sep 2017

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (13)

Daniela Duarte‐Bateman, Alan Shen, Taylor Bullock, Payam Sadeghi, Joseph M. Escandón, Eliska Dedkova & Brian R. Gastman. (2022) Best practices in surgical and nonsurgical management of head and neck Merkel cell carcinoma: An update. Molecular Carcinogenesis 62:1, pages 101-112.
Crossref

Emily J. Koubek, Jillian S. Weissenrieder, Luz E. Ortiz, Nnenna Nwogu, Alexander M. Pham, J. Dylan Weissenkampen, Jessie L. Reed, Jeffrey D. Neighbors, Raymond J. Hohl & Hyun Jin Kwun. (2022) Therapeutic Potential of 5′-Methylschweinfurthin G in Merkel Cell Polyomavirus-Positive Merkel Cell Carcinoma. Viruses 14:9, pages 1848.
Crossref

Wyatt Lydolph, Sai Prasad Desikan, Shiyu Wang, John Allgood, Charles McClainsIIIIII, Jennifer Mclaughlin & Raman Desikan. (2022) Advances in Immunology: A Cornerstone in Diagnosis and Therapy of Merkel Cell Carcinoma. Journal of Investigative Medicine High Impact Case Reports 10, pages 232470962210894.
Crossref

Gianluca Ricco, Elisa Andrini, Giambattista Siepe, Cristina Mosconi, Valentina Ambrosini, Claudio Ricci, Riccardo Casadei, Davide Campana & Giuseppe Lamberti. (2021) Multimodal Strategy in Localized Merkel Cell Carcinoma: Where Are We and Where Are We Heading?. International Journal of Molecular Sciences 22:19, pages 10629.
Crossref

Gurmanpreet Kaur & Nabiha Yusuf. 2021. Skin Cancer: Pathogenesis and Diagnosis. Skin Cancer: Pathogenesis and Diagnosis 69 77 .

Rocio Garcia-Carbonero, Ivan Marquez-Rodas, Luis de la Cruz-Merino, Javier Martinez-Trufero, Miguel Angel Cabrera, Jose Maria Piulats, Jaume Capdevila, Enrique Grande, Salvador Martin-Algarra & Alfonso Berrocal. (2019) Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma. The Oncologist 24:10, pages 1375-1383.
Crossref

Daniel R Principe, Joseph I Clark, Bahman Emami & Stanley Borowicz. (2019) Combined radio-immunotherapy leads to complete clinical regression of stage IV Merkel cell carcinoma. BMJ Case Reports 12:8, pages e230518.
Crossref

Dawn Queen, Yuhan Gu, Adriana Lopez, Diane Chen & Larisa J. Geskin. (2019) Paraneoplastic cerebellar ataxia in Merkel cell carcinoma of unknown primary. JAAD Case Reports 5:5, pages 398-400.
Crossref

Marco Gallo, Valentina Guarnotta, Federica De Cicco, Manila Rubino, Antongiulio Faggiano & Annamaria Colao. (2019) Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions. Journal of Cancer Research and Clinical Oncology 145:2, pages 429-443.
Crossref

Rafael A. SchmerlingJose G. CasasGabriela CinatFabio Ernesto Grosso OspinaLuiza E.B.P. KassugaJorge Luis Martinez TlahuelLuis Daniel Mazzuoccolo. (2018) Burden of Disease, Early Diagnosis, and Treatment of Merkel Cell Carcinoma in Latin America. Journal of Global Oncology:4, pages 1-11.
Crossref

Yasiru G. Karunaratne, Dakshika A. Gunaratne & Michael J. Veness. (2018) Systematic review of sentinel lymph node biopsy in Merkel cell carcinoma of the head and neck. Head & Neck 40:12, pages 2704-2713.
Crossref

Noah A. Kolb, Christopher R Trevino, Waqar Waheed, Fatemeh Sobhani, Kara K. Landry, Alissa A. Thomas & Mike Hehir. (2018) Neuromuscular complications of immune checkpoint inhibitor therapy. Muscle & Nerve 58:1, pages 10-22.
Crossref

Naghmehossadat Eshghi, Tamara F. Lundeen, Lea MacKinnon, Ryan Avery & Phillip H. Kuo. (2018) 18F-FDG PET/CT for Monitoring Response of Merkel Cell Carcinoma to the Novel Programmed Cell Death Ligand 1 Inhibitor Avelumab. Clinical Nuclear Medicine 43:5, pages e142-e144.
Crossref

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Is this the end of cytotoxic chemotherapy in Merkel cell carcinoma?

Articles from other publishers (13)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Is this the end of cytotoxic chemotherapy in Merkel cell carcinoma?

Citations (13)

Articles from other publishers (13)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date